Product logins

Find logins to all Clarivate products below.


Biosimilars | Emerging Biosimilars | Truxima Launch Tracker | Germany | Wave 1 | 2017

In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we track German physicians’ awareness of Truxima and its uptake since its launch to understand how its entry will impact the non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and the increasingly competitive immune biologics market. Along with physicians’ awareness of, familiarity with, and perceptions of biosimilars in general and of Truxima specifically, we explore the drivers of and barriers to the uptake of biosimilars/Truxima. We examine promotional efforts, as well as prescriber and nonprescriber profiles, and compare Truxima with other available biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered

  • Are German physicians aware of Truxima and its clinical development?
  • What are the drivers to prescribing Truxima? What is the current level of Truxima use, and how is it changing over time?
  • Has experience with Truxima changed physicians’ opinions of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima to patients?
  • What promotional messages are sales representatives using to sell Truxima and MabThera?

Related Market Assessment Reports

Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…
Report
Biosimilars – Forecast – Neurology
In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the…
Report
Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3…